Developer docs
API playgroundTry for free, no card

Search company profiles

Mikart

Full company profile

uuid0007jqe

Namestring
Mikart
Legal namestring
Mikart, LLC
Websiteurl
mikart.com
Company typeenum
Private
Founded yearint
1975
Descriptiontext

Mikart is a U.S.-based contract development and manufacturing organization (CDMO) founded in 1975 in Atlanta, Georgia, specializing in oral solid and non-sterile oral liquid dosage forms across the full development-to-commercialization lifecycle. The company's platform spans pre-formulation and formulation development, non-GMP small-scale laboratory work (eight suites), analytical method development, GMP manufacturing (50L–4,000L liquids, controlled substance suites, pediatric/geriatric formats), and full-service packaging including bottle filling, blister, pouch/foil, cartoning, unit-dose cups, and DSCSA-compliant serialization via OPTEL and TraceLink. Differentiated capabilities include DEA Schedule I–V controlled substance licensing, licensed NanoTransformer™ (nanoformulation) and Microcoat™ (taste-masking) technology platforms, nitrogen-purged liquid/suspension suites, and 2023 DSCSA-compliant serialization.

Mikart serves virtual to mid-sized pharmaceutical and biotech companies requiring outsourced CMC and regulatory capabilities, as well as specialty use-cases in controlled substances (opioids, cannabinoids, psychedelics), pediatric and geriatric formulations, and liquid oral products for dysphagia and palatability-challenged populations. Customer engagements run from preclinical through commercial supply and are supported by a dedicated project manager model with direct CEO-level engagement at kickoff. GTM is direct enterprise sales via a business development team (BizDev@mikart.com), supplemented by thought leadership (white papers, webinars, blog), industry events, PR/news wires, and organic social — there are no resellers, distributors, or marketplace channels.

The company has been PE-backed since 2018 (the Arteche family retained control for the prior 43 years), and the PE sponsor has driven a multi-year transformation from focused generic manufacturer to integrated CDMO with expanded capabilities. Recent milestones include a 50%+ expansion in oral solid dosage bottling capacity (operational startup Q4 2026), new executive headquarters at Cumberland Center II in Northwest Atlanta (ribbon cutting April 28, 2026), a strategic co-marketing partnership with Benuvia Operations (April 2026) for controlled substances and complex APIs, and the addition of nitrogen-purged liquid/suspension suites (October 2024). Revenue is generated through project-based, quote-priced contracts for development, manufacturing, analytical, regulatory, and packaging services across clinical and commercial stages.

Short descriptiontext

Mikart is a U.S. CDMO specializing in oral solid and non-sterile oral liquid dosage forms, serving virtual to mid-sized pharma and biotech companies with DEA Schedule I–V controlled-substance capabilities, formulation development, GMP manufacturing, and DSCSA-compliant packaging from preclinical through commercial supply.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAtlanta, United States
HQ citystring
Atlanta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical contract manufacturing, oral solid dosage forms, controlled substance manufacturing, pharmaceutical development services, pharmaceutical packaging services
Industry4 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development & Manufacturing (CDMO) Services
TypeProfessional Services
Description

Mikart provides end-to-end pharmaceutical development and manufacturing services from pre-formulation through commercial-scale GMP production and serialized packaging. Revenue is generated through project-based contracts, service fees for formulation development, manufacturing runs, analytical testing, regulatory support, and packaging services. Pricing is quote-based given the bespoke nature of CDMO engagements.

mikart.com
2Oral Solid & Liquid Dosage Manufacturing
TypeHardware Sales
Description

Manufacturing revenue derived from commercial-scale production of oral solid (tablets, capsules) and non-sterile oral liquid (solutions, suspensions) dosage forms, including controlled substances (Schedule I–V) and pediatric/geriatric formulations.

mikart.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Mikart is a U.S.-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services spanning pre-formulation, formulation development, GMP manufacturing, analytical testing, regulatory support, and serialized packaging for oral solid dosage forms (tablets, capsules) and non-sterile oral liquid dosage forms (solutions, suspensions). The company holds DEA Schedule I–V licensing for controlled substance development and manufacturing, and serves virtual to mid-sized pharmaceutical and biotech companies from non-GMP early-phase development through commercial-scale GMP production.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Seamless transition from non-GMP early-phase to GMP commercial manufacturing without development rework or delays.
+2 more records
Product overview1 text field

Mikart is a Contract Development and Manufacturing Organization (CDMO) founded in 1975, offering an integrated platform of pharmaceutical development, manufacturing, and packaging services. The company's core offering spans oral solid dosage forms (tablets, capsules, powder in bottle) and non-sterile oral liquid dosage forms (solutions, suspensions), with specialized capabilities in controlled substances (Schedule I-V DEA-licensed), pediatric formulations, and geriatric formulations. Mikart provides end-to-end services from non-GMP early-phase development through clinical trial supplies to commercial-scale GMP manufacturing, complemented by full-service packaging including bottle filling, unit dose cups, blister packaging, cartoning, pouch/foil strip packs, and serialization. The company operates nitrogen-purged liquid/suspension suites and recently expanded into a new Atlanta headquarters with over 50% increased bottling capacity. Key technology partnerships include Nano PharmaSolutions (NanoTransformer nanoformulation) and Fluid Pharma (Microcoat taste-masking coating technology).

Product and service11 records
1Pharmaceutical Development Services
CategoryPharmaceutical Development
Description

Comprehensive early-phase drug development services including pre-formulation, formulation development for pediatric and geriatric populations, pharmaceutical regulatory support, non-GMP small-scale laboratory, and analytical method development for pharmaceutical and biotech clients.

2Pharmaceutical Manufacturing
CategoryPharmaceutical Manufacturing
Description

GMP manufacturing of oral solid (tablets, capsules) and non-sterile oral liquid (solutions, suspensions) dosage forms from clinical trial supplies through commercial-scale production for pharmaceutical and biotech clients.

3Controlled Substances Manufacturing (CI–CV)
CategoryControlled Substance Manufacturing
Description

DEA-licensed development and manufacturing of controlled substances across all schedules (Schedule I–V), including secure storage, handling, and cGMP-compliant manufacturing for controlled drug products such as opioids, cannabinoids, and psychedelics.

4Clinical Trial Supplies
CategoryClinical Trial Manufacturing
Description

Manufacturing and packaging of clinical trial materials including clinical trial labeling, packaging, and manufacturing services for Phase I through Phase III clinical programs.

5Oral Solid Dosage Form Manufacturing
CategoryOral Solid Dosage Manufacturing
Description

GMP manufacturing of oral solid dosage forms including tablets, capsules, and powder-in-bottle formulations for pharmaceutical clients.

6Liquids and Suspensions Manufacturing
CategoryOral Liquid Dosage Manufacturing
Description

Manufacturing of non-sterile oral liquid dosage forms including solutions and suspensions, with nitrogen-purged capability for oxidation-sensitive products and capacity ranging from 50L to 4,000L.

7Pharmaceutical Packaging Service
CategoryPharmaceutical Packaging
Description

Full-service pharmaceutical packaging including blister packaging, pouch/foil strip packs, cartoning/tray packaging, unit dose cups, bottle filling, and serialized packaging for commercial and clinical trial materials.

8Pharmaceutical Regulatory Support
CategoryRegulatory Affairs
Description

Regulatory affairs services supporting IND, NDA, ANDA, and 505(b)(2) submissions with FDA compliance and documentation practices.

9Analytical Method Development
CategoryAnalytical Services
Description

Phase-appropriate analytical method development and validation supporting pharmaceutical product release, stability testing, and shelf-life determination, compliant with FDA, CFR, and ICH guidelines.

10Non-GMP Small-Scale Laboratory Services
CategoryEarly-Phase Development
Description

Early-stage product development laboratory with 8 non-GMP suites for rapid prototyping, formulation feasibility studies, optimization, and process development prior to scale-up to GMP manufacturing.

11Serialization Services
CategoryPharmaceutical Packaging
Description

2023 DSCSA-compliant serialization capabilities offering unit-level traceability and aggregation from lowest unit of sale to pallet using OPTEL equipment and TraceLink data management, including returned product verification.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Benuvia Operations, LLC
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-04-01
Description

Strategic co-marketing partnership combining Mikart's formulation development and finished dose manufacturing capabilities with Benuvia's expertise in controlled substances, complex APIs, and psychedelics. Creates a unified U.S.-based CDMO offering spanning API development through finished drug product manufacturing. Jointly promotes services globally targeting controlled substances, cannabinoids, and emerging therapeutic categories. Includes coordinated industry events and customer outreach.

prnewswire.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-01-01
Description

Technology partnership licensing NanoTransformer™ platform for nanoformulation of poorly soluble drugs. Mikart uses this technology to produce clinical trial materials for clients with BCS Class II/IV compounds. The technology generates stable drug nanoparticles using no additives, enabling nano-granules suitable for preclinical oral gavage and first-in-human powder-in-capsule from a single formulation — accelerating timelines and reducing API requirements.

3Fluid Pharma
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-01-01
Description

Technology partnership licensing Microcoat™ technology for taste-masking and modified-release oral liquid formulations. Enables coating of very small particles (under 100 microns) without agglomeration — a significant manufacturing challenge overcome. Supports more stable suspension products, reconstitutable suspensions, ODTs, chewables, and other patient-friendly dosage forms for pediatric and geriatric populations.

mikart.com
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2015-01-01
Description

Serialization equipment provider contracted to implement DSCSA-compliant serialization on Mikart's packaging lines. OPTEL provides hardware and integration services enabling unit-level traceability from manufacturing through distribution.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2015-01-01
Description

Serialized data management and verification platform contracted to manage and verify serialized product data, enabling DSCSA compliance, aggregation tracking, and EPCIS event data generation for Mikart's customers.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Quotient Sciences offers integrated drug development services including formulation and clinical manufacturing, with particular strength in early-phase and poorly soluble API work. Overlaps with Mikart's NanoTransformer-enabled preclinical-to-first-in-human platform and rapid early-phase formulation cycles.

2Tapemark
TypeDirect peer
Description

Tapemark is a contract manufacturer specializing in transdermal patches, unit-dose liquids, and other specialty dose forms for pharma, with packaging capabilities including serialization — a direct peer for Mikart's liquids/suspensions manufacturing and serialized packaging business.

TypeBroad incumbent
Description

Hovione is a global CDMO with strengths in API and drug product development including oral solids and complex formulations. Overlaps with Mikart's integrated API–drug-product development capabilities and complex formulation technology.

TypeDirect peer
Description

Adare is a CDMO with deep pediatric and geriatric formulation expertise, taste-masking technology, and oral solid/liquid manufacturing — directly comparable to Mikart's Microcoat-enabled taste-masking for pediatric/geriatric populations.

TypeBroad incumbent
Description

PCI is a global integrated CDMO with strong commercial packaging, serialization, and oral solid dose capabilities. Overlaps with Mikart on serialization/DSCSA services and commercial bottling scale, but operates at significantly larger scale across multiple modalities.

6Particle Sciences (Lubrizol)
TypeDirect peer
Description

Particle Sciences (acquired by Lubrizol Life Science) is a CDMO specializing in complex drug formulations including nanoformulations, controlled substances, and patient-centric dosage forms — a strong analog to Mikart's poorly-soluble API and specialty controlled-substance capabilities.

TypeBroad incumbent
Description

Catalent is a global, broad-portfolio CDMO serving oral solid, sterile, biologics, and specialty dose forms across large and small pharma. Comparable as a broader incumbent CDMO with overlap in oral solid dose manufacturing and clinical-to-commercial supply.

TypeDirect peer
Description

CoreRx is a mid-sized U.S. CDMO specializing in liquid and solid oral dose forms, controlled substances, and complex formulation development — directly comparable to Mikart in customer base (virtual-to-mid pharma), technology stack, and dosage form focus.

TypeDirect peer
Description

Halo Pharma is a mid-sized CDMO offering oral solid and liquid dose manufacturing, pediatric formulations, and small-mid pharma focused commercial supply — competing head-to-head with Mikart on dosage forms and customer profile.

TypeDirect peer
Description

Ascendia is a specialty CDMO focused on complex formulations, poorly soluble APIs, and small-batch injectable and oral dose manufacturing for niche pharma clients — overlapping closely with Mikart's NanoTransformer-enabled solubility work and small-mid pharma target market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mikart

Pharmaceutical Contract Development and Manufacturing (CDMO)mikart.com

Mikart is a U.S. CDMO specializing in oral solid and non-sterile oral liquid dosage forms, serving virtual to mid-sized pharma and biotech companies with DEA Schedule I–V controlled-substance capabilities, formulation development, GMP manufacturing, and DSCSA-compliant packaging from preclinical through commercial supply.

What Mikart does

Mikart is a U.S.-based contract development and manufacturing organization (CDMO) founded in 1975 in Atlanta, Georgia, specializing in oral solid and non-sterile oral liquid dosage forms across the full development-to-commercialization lifecycle. The company's platform spans pre-formulation and formulation development, non-GMP small-scale laboratory work (eight suites), analytical method development, GMP manufacturing (50L–4,000L liquids, controlled substance suites, pediatric/geriatric formats), and full-service packaging including bottle filling, blister, pouch/foil, cartoning, unit-dose cups, and DSCSA-compliant serialization via OPTEL and TraceLink. Differentiated capabilities include DEA Schedule I–V controlled substance licensing, licensed NanoTransformer™ (nanoformulation) and Microcoat™ (taste-masking) technology platforms, nitrogen-purged liquid/suspension suites, and 2023 DSCSA-compliant serialization.

Mikart serves virtual to mid-sized pharmaceutical and biotech companies requiring outsourced CMC and regulatory capabilities, as well as specialty use-cases in controlled substances (opioids, cannabinoids, psychedelics), pediatric and geriatric formulations, and liquid oral products for dysphagia and palatability-challenged populations. Customer engagements run from preclinical through commercial supply and are supported by a dedicated project manager model with direct CEO-level engagement at kickoff. GTM is direct enterprise sales via a business development team (BizDev@mikart.com), supplemented by thought leadership (white papers, webinars, blog), industry events, PR/news wires, and organic social — there are no resellers, distributors, or marketplace channels.

The company has been PE-backed since 2018 (the Arteche family retained control for the prior 43 years), and the PE sponsor has driven a multi-year transformation from focused generic manufacturer to integrated CDMO with expanded capabilities. Recent milestones include a 50%+ expansion in oral solid dosage bottling capacity (operational startup Q4 2026), new executive headquarters at Cumberland Center II in Northwest Atlanta (ribbon cutting April 28, 2026), a strategic co-marketing partnership with Benuvia Operations (April 2026) for controlled substances and complex APIs, and the addition of nitrogen-purged liquid/suspension suites (October 2024). Revenue is generated through project-based, quote-priced contracts for development, manufacturing, analytical, regulatory, and packaging services across clinical and commercial stages.

Mikart firmographics

Firmographics
Name
Mikart
Legal name
Mikart, LLC
Website
https://mikart.com
Company type
Private
Founded year
1975
Operating status
Operating
Headcount range
101–250 employees
Short description
Mikart is a U.S. CDMO specializing in oral solid and non-sterile oral liquid dosage forms, serving virtual to mid-sized pharma and biotech companies with DEA Schedule I–V controlled-substance capabilities, formulation development, GMP manufacturing, and DSCSA-compliant packaging from preclinical through commercial supply.
Ownership category
akta.pro rank

Mikart industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Pharmaceutical contract manufacturing
  • Oral solid dosage forms
  • Controlled substance manufacturing
  • Pharmaceutical development services
  • Pharmaceutical packaging services

Where Mikart is headquartered

Location

Headquarters

HQ city
Atlanta
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Mikart business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Development & Manufacturing (CDMO) Services: Mikart provides end-to-end pharmaceutical development and manufacturing services from pre-formulation through commercial-scale GMP production and serialized packaging. Revenue is generated through project-based contracts, service fees for formulation development, manufacturing runs, analytical testing, regulatory support, and packaging services. Pricing is quote-based given the bespoke nature of CDMO engagements.
  2. Oral Solid & Liquid Dosage Manufacturing: Manufacturing revenue derived from commercial-scale production of oral solid (tablets, capsules) and non-sterile oral liquid (solutions, suspensions) dosage forms, including controlled substances (Schedule I–V) and pediatric/geriatric formulations.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Mikart product offering

Product offering

Core offering

Mikart is a U.S.-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services spanning pre-formulation, formulation development, GMP manufacturing, analytical testing, regulatory support, and serialized packaging for oral solid dosage forms (tablets, capsules) and non-sterile oral liquid dosage forms (solutions, suspensions). The company holds DEA Schedule I–V licensing for controlled substance development and manufacturing, and serves virtual to mid-sized pharmaceutical and biotech companies from non-GMP early-phase development through commercial-scale GMP production.

Product overview

Mikart is a Contract Development and Manufacturing Organization (CDMO) founded in 1975, offering an integrated platform of pharmaceutical development, manufacturing, and packaging services. The company's core offering spans oral solid dosage forms (tablets, capsules, powder in bottle) and non-sterile oral liquid dosage forms (solutions, suspensions), with specialized capabilities in controlled substances (Schedule I-V DEA-licensed), pediatric formulations, and geriatric formulations. Mikart provides end-to-end services from non-GMP early-phase development through clinical trial supplies to commercial-scale GMP manufacturing, complemented by full-service packaging including bottle filling, unit dose cups, blister packaging, cartoning, pouch/foil strip packs, and serialization. The company operates nitrogen-purged liquid/suspension suites and recently expanded into a new Atlanta headquarters with over 50% increased bottling capacity. Key technology partnerships include Nano PharmaSolutions (NanoTransformer nanoformulation) and Fluid Pharma (Microcoat taste-masking coating technology).

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical Development Services Comprehensive early-phase drug development services including pre-formulation, formulation development for pediatric and geriatric populations, pharmaceutical regulatory support, non-GMP small-scale laboratory, and analytical method development for pharmaceutical and biotech clients.
  • Pharmaceutical Manufacturing GMP manufacturing of oral solid (tablets, capsules) and non-sterile oral liquid (solutions, suspensions) dosage forms from clinical trial supplies through commercial-scale production for pharmaceutical and biotech clients.
  • Controlled Substances Manufacturing (CI–CV) DEA-licensed development and manufacturing of controlled substances across all schedules (Schedule I–V), including secure storage, handling, and cGMP-compliant manufacturing for controlled drug products such as opioids, cannabinoids, and psychedelics.
  • Clinical Trial Supplies Manufacturing and packaging of clinical trial materials including clinical trial labeling, packaging, and manufacturing services for Phase I through Phase III clinical programs.
  • Oral Solid Dosage Form Manufacturing GMP manufacturing of oral solid dosage forms including tablets, capsules, and powder-in-bottle formulations for pharmaceutical clients.
  • Liquids and Suspensions Manufacturing Manufacturing of non-sterile oral liquid dosage forms including solutions and suspensions, with nitrogen-purged capability for oxidation-sensitive products and capacity ranging from 50L to 4,000L.
  • Pharmaceutical Packaging Service Full-service pharmaceutical packaging including blister packaging, pouch/foil strip packs, cartoning/tray packaging, unit dose cups, bottle filling, and serialized packaging for commercial and clinical trial materials.
  • Pharmaceutical Regulatory Support Regulatory affairs services supporting IND, NDA, ANDA, and 505(b)(2) submissions with FDA compliance and documentation practices.
  • Analytical Method Development Phase-appropriate analytical method development and validation supporting pharmaceutical product release, stability testing, and shelf-life determination, compliant with FDA, CFR, and ICH guidelines.
  • Non-GMP Small-Scale Laboratory Services Early-stage product development laboratory with 8 non-GMP suites for rapid prototyping, formulation feasibility studies, optimization, and process development prior to scale-up to GMP manufacturing.
  • Serialization Services 2023 DSCSA-compliant serialization capabilities offering unit-level traceability and aggregation from lowest unit of sale to pallet using OPTEL equipment and TraceLink data management, including returned product verification.

Quantifiable outcome

  • Seamless transition from non-GMP early-phase to GMP commercial manufacturing without development rework or delays.
  • +2 more outcomes

Companies that use Mikart

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Mikart technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Mikart partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and supporting.

  • Benuvia Operations, LLCcoreGTM or Marketing Partner · 1 April 2026Strategic co-marketing partnership combining Mikart's formulation development and finished dose manufacturing capabilities with Benuvia's expertise in controlled substances, complex APIs, and psychedelics. Creates a unified U.S.-based CDMO offering spanning API development through finished drug product manufacturing. Jointly promotes services globally targeting controlled substances, cannabinoids, and emerging therapeutic categories. Includes coordinated industry events and customer outreach.
  • Nano PharmaSolutionscoreTechnology or Integration · 1 January 2022Technology partnership licensing NanoTransformer™ platform for nanoformulation of poorly soluble drugs. Mikart uses this technology to produce clinical trial materials for clients with BCS Class II/IV compounds. The technology generates stable drug nanoparticles using no additives, enabling nano-granules suitable for preclinical oral gavage and first-in-human powder-in-capsule from a single formulation — accelerating timelines and reducing API requirements.
  • Fluid PharmacoreTechnology or Integration · 1 January 2022Technology partnership licensing Microcoat™ technology for taste-masking and modified-release oral liquid formulations. Enables coating of very small particles (under 100 microns) without agglomeration — a significant manufacturing challenge overcome. Supports more stable suspension products, reconstitutable suspensions, ODTs, chewables, and other patient-friendly dosage forms for pediatric and geriatric populations.
  • OPTELsupportingTechnology or Integration · 1 January 2015Serialization equipment provider contracted to implement DSCSA-compliant serialization on Mikart's packaging lines. OPTEL provides hardware and integration services enabling unit-level traceability from manufacturing through distribution.
  • TraceLinksupportingTechnology or Integration · 1 January 2015Serialized data management and verification platform contracted to manage and verify serialized product data, enabling DSCSA compliance, aggregation tracking, and EPCIS event data generation for Mikart's customers.

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Mikart competitors and assessment

Company assessment

Emerging players

  • Quotient Sciences: Quotient Sciences offers integrated drug development services including formulation and clinical manufacturing, with particular strength in early-phase and poorly soluble API work. Overlaps with Mikart's NanoTransformer-enabled preclinical-to-first-in-human platform and rapid early-phase formulation cycles.

Direct peers

  • Tapemark: Tapemark is a contract manufacturer specializing in transdermal patches, unit-dose liquids, and other specialty dose forms for pharma, with packaging capabilities including serialization — a direct peer for Mikart's liquids/suspensions manufacturing and serialized packaging business.
  • Adare Pharma Solutions: Adare is a CDMO with deep pediatric and geriatric formulation expertise, taste-masking technology, and oral solid/liquid manufacturing — directly comparable to Mikart's Microcoat-enabled taste-masking for pediatric/geriatric populations.
  • Particle Sciences (Lubrizol): Particle Sciences (acquired by Lubrizol Life Science) is a CDMO specializing in complex drug formulations including nanoformulations, controlled substances, and patient-centric dosage forms — a strong analog to Mikart's poorly-soluble API and specialty controlled-substance capabilities.
  • CoreRx: CoreRx is a mid-sized U.S. CDMO specializing in liquid and solid oral dose forms, controlled substances, and complex formulation development — directly comparable to Mikart in customer base (virtual-to-mid pharma), technology stack, and dosage form focus.
  • Halo Pharma: Halo Pharma is a mid-sized CDMO offering oral solid and liquid dose manufacturing, pediatric formulations, and small-mid pharma focused commercial supply — competing head-to-head with Mikart on dosage forms and customer profile.
  • Ascendia Pharmaceuticals: Ascendia is a specialty CDMO focused on complex formulations, poorly soluble APIs, and small-batch injectable and oral dose manufacturing for niche pharma clients — overlapping closely with Mikart's NanoTransformer-enabled solubility work and small-mid pharma target market.

Broad incumbents

  • Hovione: Hovione is a global CDMO with strengths in API and drug product development including oral solids and complex formulations. Overlaps with Mikart's integrated API–drug-product development capabilities and complex formulation technology.
  • PCI Pharma Services: PCI is a global integrated CDMO with strong commercial packaging, serialization, and oral solid dose capabilities. Overlaps with Mikart on serialization/DSCSA services and commercial bottling scale, but operates at significantly larger scale across multiple modalities.
  • Catalent Pharma Solutions: Catalent is a global, broad-portfolio CDMO serving oral solid, sterile, biologics, and specialty dose forms across large and small pharma. Comparable as a broader incumbent CDMO with overlap in oral solid dose manufacturing and clinical-to-commercial supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Mikart social profiles

Digital presence

Mikart financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mikart leadership team

Management profile

Number of profiles

Profiles5 records

Mikart funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mikart M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mikart

What does Mikart do?

Mikart is a U.S.-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services spanning pre-formulation, formulation development, GMP manufacturing, analytical testing, regulatory support, and serialized packaging for oral solid dosage forms (tablets, capsules) and non-sterile oral liquid dosage forms (solutions, suspensions). The company holds DEA Schedule I–V licensing for controlled substance development and manufacturing, and serves virtual to mid-sized pharmaceutical and biotech companies from non-GMP early-phase development through commercial-scale GMP production.

Is Mikart a public or private company?

Mikart is a private company. It is classified as private equity controlled and is currently operating.

When was Mikart founded?

Mikart was founded in 1975. It employs 101 to 250 people.

Where is Mikart based?

Mikart is headquartered in Atlanta, United States, in the North America region.

How does Mikart make money?

Two revenue lines are on record. Contract Development & Manufacturing (CDMO) Services are the primary driver. The others are oral Solid & Liquid Dosage Manufacturing.

Who are Mikart's main competitors?

Quotient Sciences is listed as an emerging player. Direct peers are Tapemark, Adare Pharma Solutions, Particle Sciences (Lubrizol), CoreRx, Halo Pharma and Ascendia Pharmaceuticals. Broad incumbents are Hovione, PCI Pharma Services and Catalent Pharma Solutions.

Does Mikart have an API?

No public API is recorded for Mikart.

What industry is Mikart in?

Mikart's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Third NewsMikart Welcomes Darrin Schellin as New CEO to Propel Future GrowthMikart, a Contract Development and Manufacturing Organization (CDMO) specializing in pharmaceutical manufacturing, has appointed Darrin T. Schellin as its new Chief Executive Officer. Schellin brings over two decades of executive leadership experience in the pharmaceutical, biotechnology, and CDMO sectors, having previously led Pharma Tech Industries and GBI Bio. This leadership transition is aimed at enhancing operational performance, expanding commercially, and maintaining quality standards at the company.PR NewswireMikart Appoints Darrin Schellin as Chief Executive OfficerMikart, a clinical and commercial CDMO headquartered in Atlanta, appointed Darrin T. Schellin as Chief Executive Officer effective July 7, 2026. Schellin brings over 20 years of executive leadership experience in the pharmaceutical, biotechnology, and CDMO sectors, most recently serving as CEO of Pharma Tech Industries where he led a transformation of its powder-based product platform. The appointment is aimed at accelerating Mikart's growth, strengthening operational excellence, and expanding the company's commercial capabilities.Precedence ResearchChemical Drug CDMO Market Size to Hit USD 29.84 Billion by 2035The global chemical drug CDMO market was valued at USD 13.20 billion in 2025 and is projected to reach USD 29.84 billion by 2035, growing at a CAGR of 8.50%, driven by rising pharmaceutical outsourcing and cost-efficient manufacturing demand. North America led with 35% market share in 2025, while Asia Pacific is expected to grow at the fastest CAGR of 12.5% through 2035. In April 2026, two strategic partnerships were announced: Mikart, LLC partnered with Benuvia Operations, LLC for controlled substances and complex API development, and HRV Pharma partnered with Shodhana Laboratories to accelerate next-generation API development using AI-enabled platforms.PR NewswireMikart Celebrates Ribbon Cutting of New Atlanta Headquarters, Marking Major Milestone in Growth and ExpansionMikart, a contract development and manufacturing organization (CDMO), held a ribbon cutting ceremony on April 28, 2026 for its new executive headquarters in Northwest Atlanta, a relocation originally announced in September 2025. The company is simultaneously advancing a manufacturing expansion that will increase oral solid dosage bottling capacity by more than 50%, with operational startup scheduled for Q4 2026. The strategic initiative is designed to strengthen Mikart's CDMO manufacturing network, improve operational resilience, and enable scalable long-term growth alongside its pharmaceutical partners.The Pharma LetterUS firms in co-marketing deal on end-to-end controlled substance development and finished drug product manufacturingMikart and Benuvia Operations announced a strategic co-marketing partnership to combine their capabilities for end-to-end controlled substance development and finished drug product manufacturing. The US companies will integrate their complementary expertise to provide fully integrated solutions spanning drug substance development through finished product manufacturing.PR NewswireMikart and Benuvia Announce Strategic Co-Marketing Partnership to Deliver End-to-End Controlled Substance Development and Finished Drug Product Manufacturing SolutionsMikart, LLC and Benuvia Operations, LLC announced a strategic co-marketing partnership to provide fully integrated, end-to-end pharmaceutical development and manufacturing solutions spanning API development through finished drug product manufacturing. The partnership combines Mikart's formulation development and finished dose manufacturing capabilities with Benuvia's expertise in controlled substances, complex APIs, and psychedelics, creating a unified U.S.-based CDMO offering. The collaboration will initially focus on controlled substances, cannabinoids, and emerging therapeutic categories, with joint business development initiatives including industry events and coordinated customer outreach.MorningstarMikart and Benuvia Announce Strategic Co-Marketing Partnership to Deliver End-to-End Controlled Substance Development and Finished Drug Product Manufacturing SolutionsMikart, LLC and Benuvia Operations, LLC announced a strategic co-marketing partnership to offer fully integrated, end-to-end pharmaceutical development and manufacturing solutions spanning drug substance (API) development through finished drug product manufacturing. The collaboration combines Mikart's formulation development and finished dose manufacturing capabilities with Benuvia's expertise in controlled substances, complex APIs, and psychedelics. The companies will jointly promote their services globally and collaborate on business development initiatives, targeting the controlled substances, cannabinoids, and emerging therapeutic categories.Pharma Tech OutlookTop Pharmaceutical Packaging CompaniesThe article discusses leading pharmaceutical packaging companies and related industry developments. It highlights firms such as Inceptua, Keystone, Legacy Pharma, Mikart, and Sharp, emphasizing their roles in pharmaceutical services and packaging innovation.PR NewswireMikart Signs Lease for New Headquarters at Cumberland Center II in Northwest AtlantaMikart, a contract development and manufacturing organization (CDMO), has signed a lease for approximately 13,000 square feet of space at Cumberland Center II in Northwest Atlanta to serve as its new headquarters. The relocation will free up capacity at its existing manufacturing campus for expanded serialized packaging operations supporting its growing oral solid dose and liquid product lines. Company executives described the move as an important step in Mikart's growth strategy, enabling reinvestment in core operations to deliver end-to-end solutions for pharmaceutical clients.MikartWhat Biotechs Should Look for in a CDMO Partner Pre-CommercializationThe article outlines seven key criteria for emerging biotech companies to consider when selecting a Contract Development and Manufacturing Organization (CDMO) partner for commercialization. It highlights the importance of proven late-stage experience, regulatory compliance, integrated development services, technical expertise in specific dosage forms, supply chain capabilities, transparent communication, and long-term partnership flexibility. Mikart is presented as an example of a CDMO provider that offers these comprehensive solutions to support clients from clinical trials to market launch.